Skip to main content

2010 | Buch

Valuation in Life Sciences

A Practical Guide

verfasst von: Boris Bogdan, Ralph Villiger

Verlag: Springer Berlin Heidelberg

insite
SUCHEN

Über dieses Buch

Valuation is a hot topic among life sciences professionals. There is no clear understanding on how to use the different valuation approaches and how to determine input parameters. Some do not value at all, arguing that it is not possible to get realistic and objective numbers out of it. Some claim it to be an art. In the following chapters we will provide the user with a concise val- tion manual, providing transparency and practical insight for all dealing with valuation in life sciences: project and portfolio managers, licensing executives, business developers, technology transfer managers, entrep- neurs, investors, and analysts. The purpose of the book is to explain how to apply discounted cash flow and real options valuation to life sciences p- jects, i.e. to license contracts, patents, and firms. We explain the fun- mentals and the pitfalls with case studies so that the reader is capable of performing the valuations on his own and repeat the theory in the exercises and case studies. The book is structured in five parts: In the first part, the introduction, we discuss the role of the players in the life sciences industry and their p- ticular interests. We describe why valuation is important to them, where they need it, and the current problems to it. The second part deals with the input parameters required for valuation in life sciences, i.e. success rates, costs, peak sales, and timelines.

Inhaltsverzeichnis

Frontmatter
Introduction
Abstract
Valuation is a hot topic among life sciences professionals. There is no clear understanding on how to use the different valuation approaches and how to determine input parameters. Some do not value at all, arguing that it is not possible to get realistic and objective numbers out of it. Some claim it to be an art.
Dr. Boris Bogdan, Ralph Villiger
Basics of Valuation
Abstract
All companies deal with valuation from time to time. Capital budgeting, company and asset valuation, or value based management rely on valuation.
Two approaches are the foundation of valuation, discounted cash flow valuation and relative valuation. The first one is a bottom-up approach where the present value of an asset’s future cash flows is calculated, the second determines the value of an asset by comparing it to similar other assets.
While relative valuation is well applicable by common sense, DCF needs considerable understanding of the relevant input parameters. As DCF is a vital approach to valuation in life sciences and the basis of decision tree analysis and real options valuation, it is worthwhile to discuss in detail how the method is properly applied.
Dr. Boris Bogdan, Ralph Villiger
Valuation in Life Sciences
Abstract
In the following part we discuss how the theory outlined in the previous chapter is applied to valuation in life science. First we look at the input parameters related to life science valuation and then at some special aspects, i.e. discounting, volatility and peak sales prediction, before moving on to the actual valuation. We start with the valuation of standard projects and then gradually move to the more complex problems. Every section includes a case study to illustrate practically how to use the theory. The exercises in the last part of the book complement the cases.
Dr. Boris Bogdan, Ralph Villiger
Exercises
Abstract
In this chapter, the reader has the opportunity to apply what he has learned earlier in the book. Step by step, we will guide the reader through project and license valuation, and repeat important details. We then also discuss more advanced topics by way of exercise. The solutions serve as a blue print and comprehension questions help the reader verifying, whether he has properly understood the topics.
Dr. Boris Bogdan, Ralph Villiger
Case Studies
Abstract
In this chapter we present four case studies. For each case a template Excel spreadsheet has been prepared. These template spreadsheets can be downloaded on www.​avance.​ch. The reader can solve the case studies as an extended exercise – a sketch of the solution for the first two cases is added at the end of each case.
Each case study addresses a specific topic. The first case, “Creating a Term-Sheet for BT-100”, is about structuring a term sheet for the buy-side. A mid-sized pharmaceutical company is interested in in-licensing a phase I project. The solution requires a well-structured Excel sheet with rNPV valuation. The solution in class takes about 2 hours.
Dr. Boris Bogdan, Ralph Villiger
Backmatter
Metadaten
Titel
Valuation in Life Sciences
verfasst von
Boris Bogdan
Ralph Villiger
Copyright-Jahr
2010
Verlag
Springer Berlin Heidelberg
Electronic ISBN
978-3-642-10820-4
Print ISBN
978-3-642-10819-8
DOI
https://doi.org/10.1007/978-3-642-10820-4